Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease

This study has been withdrawn prior to enrollment.
(Sponsors decision)
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01269320
First received: January 3, 2011
Last updated: August 27, 2012
Last verified: August 2011
  Purpose

This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.

Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions.

Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.


Condition Intervention Phase
Nash
Drug: Femarelle
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Hadassah Medical Organization:

Enrollment: 0
Study Start Date: January 2012
Intervention Details:
    Drug: Femarelle
    Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Biopsy proven NASH
  2. If suffering from diabetes may be treated by up to 2 oral medications, with stable doses for 2 months.
  3. If participating in sexual activity that could lead to pregnancy, the study volunteer must agree that two reliable methods of contraception will be used simultaneously while receiving the protocol-specified medication and for 1 month after stopping the medication.

    NOTE: Hormonal-based methods alone are not sufficient. At least two of the following methods MUST be used appropriately unless documentation of menopause, sterilization, or azoospermia is present:

    • Condoms (male or female) with or without a spermicidal agent. - Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission
    • Diaphragm or cervical cap with spermicide
    • IUD
    • Hormonal-based contraception

    Study subjects who are not of reproductive potential (girls who have not reached menarche or women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy and/or bilateral oophorectomy are eligible without requiring the use of contraceptives. Written or oral documentation communicated by clinician or clinician's staff is required by one of the following:

    • Physician report/letter
    • Operative report or other source documentation in the patient record (a laboratory report of azoospermia is required to document successful vasectomy)
    • Discharge summary
    • Laboratory report of azoospermia
    • FSH measurement elevated into the menopausal range as established by the reporting laboratory.
  4. Ability and willingness of subject or legal guardian/representative to provide informed consent.

Exclusion Criteria:

  1. Pregnancy or Breast-Feeding
  2. Continuous use of the following medications for more than 3 days within 30 days of study entry:

    • Immunosuppressives
    • Immune modulators
    • Systemic glucocorticoids
    • Anti-neoplastic agents
  3. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  4. Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.
  5. Surgery within the previous 3 months.
  6. Any serious infectious, cardiac, pulmonary, or kidney disease
  7. Hypersensitivity to Femarelle ®
  8. Malignancy of the uterus or breast
  9. Past thromboembolic event
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01269320

Locations
Israel
Hadassah Medical Organization, Jerusalem, Israel
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01269320     History of Changes
Other Study ID Numbers: 0172-10-HMO-CTIL
Study First Received: January 3, 2011
Last Updated: August 27, 2012
Health Authority: Israel: Ministry of Health - Director General

ClinicalTrials.gov processed this record on September 30, 2014